<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32404191</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>Molecular brain</Title><ISOAbbreviation>Mol Brain</ISOAbbreviation></Journal><ArticleTitle>Frameshift peptides alter the properties of truncated FUS proteins in ALS-FUS.</ArticleTitle><Pagination><StartPage>77</StartPage><MedlinePgn>77</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">77</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13041-020-00618-0</ELocationID><Abstract><AbstractText>Mutations in the FUS gene cause a subset of ALS cases (ALS-FUS). The majority of FUS mutations are missense mutations affecting the nuclear localisation signal (NLS) of FUS. In addition, a number of frameshift mutations which result in complete NLS deletion have been described. Patients bearing frameshift mutations usually present with more aggressive disease, characterised by an early onset and rapid progression. Both missense mutations in the NLS coding sequence and complete loss of the NLS are known to result in cytoplasmic mislocalisation of FUS protein. However, in addition to the removal of FUS functional domains, frameshift mutations in most cases lead to the attachment of a "tail" of novel amino acids at the FUS C-terminus - a frameshift peptide. It is not clear whether these peptide tails would affect the properties of truncated FUS proteins. In the current study, we compared intracellular behaviour of disease-associated truncated FUS proteins with and without the corresponding frameshift peptides. We demonstrate that some of these peptides can affect subcellular distribution and/or increase aggregation capacity and stability of the truncated FUS protein. Our study suggests that frameshift peptides can alter the properties of truncated FUS variants which may modulate FUS pathogenicity and contribute to the variability of the disease course in ALS-FUS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>An</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medicines Discovery Institute, Cardiff University, Cardiff, CF10 3AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedicine Division, School of Biosciences, Cardiff University, Park Place, Cardiff, CF10 3AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabesahala de Meritens</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medicines Discovery Institute, Cardiff University, Cardiff, CF10 3AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>Vladimir L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Biomedicine Division, School of Biosciences, Cardiff University, Park Place, Cardiff, CF10 3AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelkovnikova</LastName><ForeName>Tatyana A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0003-1367-5309</Identifier><AffiliationInfo><Affiliation>Medicines Discovery Institute, Cardiff University, Cardiff, CF10 3AT, UK. shelkovnikovat@cardiff.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedicine Division, School of Biosciences, Cardiff University, Park Place, Cardiff, CF10 3AT, UK. shelkovnikovat@cardiff.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BUCHMAN/APR13/822-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MRF_MRF-060-0001-RG-SHELK</GrantID><Acronym>MRF</Acronym><Agency>MRF</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SHELKOVNIKOVA/OCT17/968-799</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Brain</MedlineTA><NlmUniqueID>101468876</NlmUniqueID><ISSNLinking>1756-6606</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019913">Nuclear Localization Signals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016368" MajorTopicYN="Y">Frameshift Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019913" MajorTopicYN="N">Nuclear Localization Signals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">Frameshift mutation</Keyword><Keyword MajorTopicYN="N">Frameshift peptide</Keyword><Keyword MajorTopicYN="N">Fused in sarcoma</Keyword><Keyword MajorTopicYN="N">Stress granule</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32404191</ArticleId><ArticleId IdType="pmc">PMC7222445</ArticleId><ArticleId IdType="doi">10.1186/s13041-020-00618-0</ArticleId><ArticleId IdType="pii">10.1186/s13041-020-00618-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat. 2013;34(6):812&#x2013;826. doi: 10.1002/humu.22319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22319</ArticleId><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol. 2014;10(6):337&#x2013;348. doi: 10.1038/nrneurol.2014.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.78</ArticleId><ArticleId IdType="pubmed">24840975</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Daoud H, St-Onge J, Desjarlais A, Bouchard JP, Dupre N, Lacomblez L, Salachas F, Pradat PF, Meininger V, et al. Identification of novel FUS mutations in sporadic cases of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12(2):113&#x2013;117. doi: 10.3109/17482968.2010.536840.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.536840</ArticleId><ArticleId IdType="pubmed">21261515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara M, Minami M, Kamei S, Suzuki N, Kato M, Aoki M. Lower motor neuron disease caused by a novel FUS/TLS gene frameshift mutation. J Neurol. 2012;259(10):2237&#x2013;2239. doi: 10.1007/s00415-012-6542-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-012-6542-2</ArticleId><ArticleId IdType="pubmed">22619056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent L, Vizard TN, Smith BN, Topp SD, Vance C, Gkazi A, Miller J, Shaw CE, Talbot K. Autosomal dominant inheritance of rapidly progressive amyotrophic lateral sclerosis due to a truncation mutation in the fused in sarcoma (FUS) gene. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):557&#x2013;562. doi: 10.3109/21678421.2014.920033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.920033</ArticleId><ArticleId IdType="pubmed">24899262</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S, Neumann M, Rosenbohm A, Birve A, Volk AE, Weishaupt JH, Meyer T, Muller U, Andersen PM, Ludolph AC. Truncating mutations in FUS/TLS give rise to a more aggressive ALS-phenotype than missense mutations: a clinico-genetic study in Germany. Eur J Neurol. 2013;20(3):540&#x2013;546. doi: 10.1111/ene.12031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12031</ArticleId><ArticleId IdType="pubmed">23217123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S, Mori A, Sakaguchi H, Suga T, Ishihara D, Ueda A, Yamashita T, Maeda Y, Uchino M, Hirano T. Sporadic juvenile amyotrophic lateral sclerosis caused by mutant FUS/TLS: possible association of mental retardation with this mutation. J Neurol. 2012;259(6):1039&#x2013;1044. doi: 10.1007/s00415-011-6292-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6292-6</ArticleId><ArticleId IdType="pubmed">22057404</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, Liu E, Donkervoort S, Zheng JG, Shi Y, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology. 2010;75(9):807&#x2013;814. doi: 10.1212/WNL.0b013e3181f07e0c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f07e0c</ArticleId><ArticleId IdType="pmc">PMC2938970</ArticleId><ArticleId IdType="pubmed">20668259</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumer D, Hilton D, Paine SM, Turner MR, Lowe J, Talbot K, Ansorge O. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75(7):611&#x2013;618. doi: 10.1212/WNL.0b013e3181ed9cde.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ed9cde</ArticleId><ArticleId IdType="pmc">PMC2931770</ArticleId><ArticleId IdType="pubmed">20668261</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Kocerha J, Finch N, Crook R, Baker M, Desaro P, Johnston A, Rutherford N, Wojtas A, Kennelly K, et al. De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum Mutat. 2010;31(5):E1377&#x2013;E1389. doi: 10.1002/humu.21241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21241</ArticleId><ArticleId IdType="pmc">PMC2922682</ArticleId><ArticleId IdType="pubmed">20232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Robinson HK, Southcombe JA, Ninkina N, Buchman VL. Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms. Hum Mol Genet. 2014;23(19):5211&#x2013;5226. doi: 10.1093/hmg/ddu243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu243</ArticleId><ArticleId IdType="pmc">PMC4159159</ArticleId><ArticleId IdType="pubmed">24842888</ArticleId></ArticleIdList></Reference><Reference><Citation>An H, Skelt L, Notaro A, Highley JR, Fox AH, La Bella V, Buchman VL, Shelkovnikova TA. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol Commun. 2019;7(1):7. doi: 10.1186/s40478-019-0658-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0658-x</ArticleId><ArticleId IdType="pmc">PMC6330737</ArticleId><ArticleId IdType="pubmed">30642400</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, Abou-Ajram C, Kremmer E, Ansorge O, Mackenzie IR, Neumann M, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 2012;31(22):4258&#x2013;4427. doi: 10.1038/emboj.2012.261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.261</ArticleId><ArticleId IdType="pmc">PMC3501225</ArticleId><ArticleId IdType="pubmed">22968170</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>